Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In contrast, a growing body of literature suggests IRAE onset is predictive of anti-programmed cell death protein 1 (PD-1) and anti-PD-L1 antibody response across a variety of solid tumors.
|
31730012 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Programmed death ligand 1 (PD-L1) has shown potential as a therapeutic target in numerous solid tumors.
|
29378617 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Purpose The anti-programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)-positive advanced solid tumors.
|
29116900 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A cohort of patients with advanced, PD-L1-positive SGC was enrolled in the nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors (KEYNOTE-028; NCT02054806).
|
29462123 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
As PD-1/PD-L1 immune checkpoint inhibitors exhibited promising clinical outcomes in various types of solid tumors, PD-1/PD-L1 blockades have been explored for the treatment of hepatocellular carcinoma (HCC).
|
29028787 |
2018 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Despite the increasing prevalence of immunotherapy across a wide range of solid tumors, little is known about the immune infiltrate and PD-L1 expression of angiomyolipoma.
|
30285856 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cancer immunotherapy with antibodies targeting immune checkpoints such as the PD-1/PD-L1 pathway have emerged as breakthrough treatment for multiple solid tumors with high response rates and durable remissions.
|
29308309 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In recent years, inhibitory checkpoints, including cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand 1 (PD-L1), have been identified to suppress anti-tumor immune responses in solid tumors.
|
29843754 |
2018 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
It presents current data on nivolumab and other checkpoint-inhibitors in solid tumors and OC specifically and depicts important topics in the management of this novel substance group, such as side effect control, diagnostic PD-1/programmed cell death-ligand 1 (PD-L1) expression assessment and management of pseudoprogression.
|
30207101 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
|
29504990 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Blockade of immune checkpoint pathways such as the programmed cell death protein 1 pathway (PD-1/PD-L1) is an emerging approach in the treatment of solid tumors.
|
28914674 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
|
29298798 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Objective response rate was assessed by central radiologic review per Response Evaluation Criteria in Solid Tumors, version 1.1, in all patients and those with programmed cell death 1 ligand 1 (PD-L1)-positive tumors.
|
29543932 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Patients with advanced solid tumors who were enrolled in the phase 1 JAVELIN Solid Tumor (1650 patients) and phase 2 JAVELIN Merkel 200 (88 patients) trials received avelumab, a human anti-PD-L1 IgG1 antibody at a dose of 10 mg/kg every 2 weeks.
|
29469949 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PD1 and PD-L1 inhibitors showed a promising anti-tumor effect in solid tumors, where a relationship between PD-L1 expression and the objective response has been evidenced.
|
30400799 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
High expression of PD-L1 protein in tumor cells or tumor microenvironment (TME) had been identified to be a logical biomarker for predicting efficacy of ICI therapy and approved by the U.S. Food and Drug Administration to be an indicator of initiating treatment for some solid tumors.
|
30323963 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immune checkpoints blockade therapies, including anti-PD-L1 and anti-PD-1, show promising anti-tumor efficacy for a various type of solid tumors.
|
30301530 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To examine the prevalence of PDL1 amplification and its utility as a response biomarker to PD-1/PD-L1 blockade in solid tumors.
|
29902298 |
2018 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PubMed, EMBASE and other databases were systematically searched for cohort or case-control studies examining the possible correlation between PD-L1 expression and OS of patients with solid tumors.
|
29435162 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Programmed death ligand 1/2 (PD-L1/PD-L2) expression has been established as a prognostic factor for various solid tumors and as a predictive factor for PD-1 blockade therapy, but scant data on its role in gallbladder cancer (GBC).
|
30055582 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Microsatellite instability (MSI) and PD-L1 expression have been shown to predict higher response to PD-1 inhibitors as highlighted by the recent approvals of pembrolizumab in treatment-refractory solid tumors with MSI status and the third-line or greater treatment of PD-L1 positive advanced gastric/GEJ cancers.
|
29991874 |
2018 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients.
|
27939400 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We carried out this systematic meta-analysis to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors.
|
28938692 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
|
29069824 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immunotherapy has moved to the center stage of cancer treatment with the recent success of trials in solid tumors with PD-1/PD-L1 axis blockade.
|
28213726 |
2017 |